PATENT CLAIM ANALYSIS

Application Number: 15772302
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "211100"]

Abstract:
A method of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of a phosphatidylinositol 3-kinase inhibitor compound or a pharmaceutically acceptable salt thereof once-per-day either on a continuous daily schedule or an intermittent schedule at about zero to about three hours prior to sleep; a therapeutic regimen comprising administration of said compound or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.

Claim (Index 1):
A method of treating or preventing a proliferative disease in a patient in need thereof, comprising administering a therapeutically effective amount of a phosphatidylinositol 3-kinase inhibitor selected from the compound of formula (I) the compound of formula (II) pictilisib, taselisib, LY2780301, copanlisib, MLN1117, and AZD8835 and a pharmaceutically acceptable salt thereof to the patient once-per-day either on a continuous daily schedule or an intermittent schedule at about zero to about three hours prior to sleep.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 91.0
- Lexical Diversity: 1.49123
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15719636', '12208227', '12763991', '14661656', '13799076']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7162300363240091
- 35 USC 102 Novelty (BERT): 0.5647789678199087
- Combined Prediction Score: 0.701084929473599
- Mean Citation Score: 350.428222
- Max Citation Score: 458.44656
- Similarity Product: 330.90971891464227

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test